These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34902436)

  • 1. Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy.
    Nassiri M; Behnam-Rasouli R; Vakili-Azghandi M; Gopalan V; Dolati P; Nourmohammadi R
    Life Sci; 2022 Jan; 289():120222. PubMed ID: 34902436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From immunotoxins to immunoRNases.
    De Lorenzo C; D'Alessio G
    Curr Pharm Biotechnol; 2008 Jun; 9(3):210-4. PubMed ID: 18673286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
    Krauss J; Arndt MA; Dübel S; Rybak SM
    Curr Pharm Biotechnol; 2008 Jun; 9(3):231-4. PubMed ID: 18673289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody fusion proteins with human ribonucleases 1 to 8.
    Wezler X; Dübel S; Schirrmann T
    Hum Antibodies; 2018; 26(4):177-192. PubMed ID: 29689715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapeutic RNases (ImmunoRNases).
    Schirrmann T; Krauss J; Arndt MA; Rybak SM; Dübel S
    Expert Opin Biol Ther; 2009 Jan; 9(1):79-95. PubMed ID: 19063695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
    Riccio G; D'Avino C; Raines RT; De Lorenzo C
    Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleases and immunoRNases as anticancer drugs.
    Rybak SM; Arndt MA; Schirrmann T; Dübel S; Krauss J
    Curr Pharm Des; 2009; 15(23):2665-75. PubMed ID: 19689337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.
    Schirrmann T; Frenzel A; Linden L; Stelte-Ludwig B; Willuda J; Harrenga A; Dübel S; Müller-Tiemann B; Trautwein M
    MAbs; 2014; 6(2):367-80. PubMed ID: 24492302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
    Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
    Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
    D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
    Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human antibody RNase fusion protein targeting CD30+ lymphomas.
    Menzel C; Schirrmann T; Konthur Z; Jostock T; Dübel S
    Blood; 2008 Apr; 111(7):3830-7. PubMed ID: 18230757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.
    Jordaan S; Akinrinmade OA; Nachreiner T; Cremer C; Naran K; Chetty S; Barth S
    Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29510557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications of Ribonucleases in Order to Enhance Cytotoxicity in Anticancer Therapy.
    Nassiri M; Gopalan V; Vakili-Azghandi M
    Curr Cancer Drug Targets; 2022; 22(5):373-387. PubMed ID: 35240973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
    Erickson HA; Jund MD; Pennell CA
    Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific targeting and elimination of EBV-transformed B cells by allergen toxins.
    Stöcker M; Klockenbring T; Huhn M; Nachreiner T; Wicklein D; Petersen A; Bauer R; Goerlich R; Fischer R; Barth S
    J Allergy Clin Immunol; 2005 Oct; 116(4):910-5. PubMed ID: 16210069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.
    De Lorenzo C; Arciello A; Cozzolino R; Palmer DB; Laccetti P; Piccoli R; D'Alessio G
    Cancer Res; 2004 Jul; 64(14):4870-4. PubMed ID: 15256457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.
    De Lorenzo C; D'Alessio G
    FEBS J; 2009 Mar; 276(6):1527-35. PubMed ID: 19220462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant immunotoxins for cancer therapy.
    Brinkmann U; Keppler-Hafkemeyer A; Hafkemeyer P
    Expert Opin Biol Ther; 2001 Jul; 1(4):693-702. PubMed ID: 11727505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.